These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 30552159)

  • 1. Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas.
    Merli M; Frigeni M; Alric L; Visco C; Besson C; Mannelli L; Di Rocco A; Ferrari A; Farina L; Pirisi M; Piazza F; Loustaud-Ratti V; Arcari A; Marino D; Sica A; Goldaniga M; Rusconi C; Gentile M; Cencini E; Benanti F; Rumi MG; Ferretti VV; Grossi P; Gotti M; Sciarra R; Tisi MC; Cano I; Zuccaro V; Passamonti F; Arcaini L
    Oncologist; 2019 Aug; 24(8):e720-e729. PubMed ID: 30552159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of new direct antiviral agents in hepatitis C virus-infected patients with diffuse large B-cell non-Hodgkin's lymphoma.
    Persico M; Aglitti A; Caruso R; De Renzo A; Selleri C; Califano C; Abenavoli L; Federico A; Masarone M
    Hepatology; 2018 Jan; 67(1):48-55. PubMed ID: 28714143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of treatment-related toxicity on outcome of HCV-positive diffuse large B-cell lymphoma in rituximab era.
    Zaky AH; Bakry R; El-sayed MI; Elwanis MA; Nabih O
    Hematology; 2014 Oct; 19(7):412-6. PubMed ID: 24620947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct-acting antivirals in relapsed or refractory hepatitis C virus-associated diffuse large B-cell lymphoma.
    Merli M; Defrancesco I; Visco C; Besson C; Di Rocco A; Arcari A; Sica A; Cencini E; Tisi MC; Frigeni M; Grossi P; Bianchi B; Mora B; Bertù L; Bruno R; Passamonti F; Arcaini L
    Leuk Lymphoma; 2020 Sep; 61(9):2122-2128. PubMed ID: 32343165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concomitant therapy with direct-acting antivirals and chemoimmunotherapy in HCV-associated diffuse large B-cell lymphoma.
    Occhipinti V; Farina L; Viganò M; Capecchi M; Labanca S; Fanetti I; Corradini P; Rumi M
    Dig Liver Dis; 2019 May; 51(5):719-723. PubMed ID: 30502232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological features and outcome of diffuse large B-cell lymphoma associated with hepatitis C virus in elderly patients: Results of the prospective 'Elderly Project' by the Fondazione Italiana Linfomi.
    Arcari A; Tabanelli V; Merli F; Marcheselli L; Merli M; Balzarotti M; Zilioli VR; Fabbri A; Cavallo F; Casaluci GM; Tucci A; Puccini B; Pennese E; Di Rocco A; Zanni M; Flenghi L; Gini G; Sartori R; Chiappella A; Usai SV; Tani M; Marino D; Arcaini L; Vallisa D; Spina M
    Br J Haematol; 2023 May; 201(4):653-662. PubMed ID: 36733229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and prognosis of antiviral therapy on hepatitis C following treatment of lymphoma in HCV-positive diffuse large-cell lymphoma.
    Tsutsumi Y; Nakayama C; Kamada K; Kikuchi R; Kudo D; Ito S; Matsuoka S; Shiratori S; Yamamoto Y; Naruse H; Teshima T
    Ann Hematol; 2017 Dec; 96(12):2057-2061. PubMed ID: 28939993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis C virus and diffuse large B-cell lymphoma: Pathogenesis, behavior and treatment.
    Visco C; Finotto S
    World J Gastroenterol; 2014 Aug; 20(32):11054-61. PubMed ID: 25170194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial.
    Johnston PB; LaPlant B; McPhail E; Habermann TM; Inwards DJ; Micallef IN; Colgan JP; Nowakowski GS; Ansell SM; Witzig TE
    Lancet Haematol; 2016 Jul; 3(7):e309-16. PubMed ID: 27374464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial.
    Huang H; Li X; Zhu J; Ye S; Zhang H; Wang W; Wu X; Peng J; Xu B; Lin Y; Cao Y; Li H; Lin S; Liu Q; Lin T
    JAMA; 2014 Dec; 312(23):2521-30. PubMed ID: 25514302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful treatment by on-demand glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in patients with diffuse large B-cell lymphoma: a case report.
    Umemura M; Suda G; Tsukamoto S; Ebata K; Takahash S; Sasaki T; Nakajima S; Hirata K; Ozasa M; Takano M; Katagiri M; Sakamoto N
    BMC Infect Dis; 2021 Apr; 21(1):389. PubMed ID: 33906643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.
    Thieblemont C; Tilly H; Gomes da Silva M; Casasnovas RO; Fruchart C; Morschhauser F; Haioun C; Lazarovici J; Grosicka A; Perrot A; Trotman J; Sebban C; Caballero D; Greil R; van Eygen K; Cohen AM; Gonzalez H; Bouabdallah R; Oberic L; Corront B; Choufi B; Lopez-Guillermo A; Catalano J; Van Hoof A; Briere J; Cabeçadas J; Salles G; Gaulard P; Bosly A; Coiffier B
    J Clin Oncol; 2017 Aug; 35(22):2473-2481. PubMed ID: 28426350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
    Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
    Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylactic antiviral therapy for hepatitis B virus surface antigen-positive patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy.
    Yamauchi N; Maruyama D; Choi I; Atsuta Y; Sakai R; Miyashita K; Moriuchi Y; Tsujimura H; Kubota N; Yamamoto G; Igarashi T; Izutsu K; Yoshida S; Kojima K; Uchida T; Inoue Y; Tsukamoto N; Ohtsuka E; Suzuki S; Inaguma Y; Ichikawa S; Gomyo H; Ushijima Y; Nosaka K; Kurata M; Tanaka Y; Ueda R; Mizokami M; Kusumoto S
    Cancer Sci; 2021 May; 112(5):1943-1954. PubMed ID: 33576088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
    Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
    Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial.
    Davies A; Cummin TE; Barrans S; Maishman T; Mamot C; Novak U; Caddy J; Stanton L; Kazmi-Stokes S; McMillan A; Fields P; Pocock C; Collins GP; Stephens R; Cucco F; Clipson A; Sha C; Tooze R; Care MA; Griffiths G; Du MQ; Westhead DR; Burton C; Johnson PWM
    Lancet Oncol; 2019 May; 20(5):649-662. PubMed ID: 30948276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis.
    Ennishi D; Maeda Y; Niitsu N; Kojima M; Izutsu K; Takizawa J; Kusumoto S; Okamoto M; Yokoyama M; Takamatsu Y; Sunami K; Miyata A; Murayama K; Sakai A; Matsumoto M; Shinagawa K; Takaki A; Matsuo K; Kinoshita T; Tanimoto M
    Blood; 2010 Dec; 116(24):5119-25. PubMed ID: 20823454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy.
    Phan J; Mazloom A; Medeiros LJ; Zreik TG; Wogan C; Shihadeh F; Rodriguez MA; Fayad L; Fowler N; Reed V; Horace P; Dabaja BS
    J Clin Oncol; 2010 Sep; 28(27):4170-6. PubMed ID: 20713859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients.
    Park YH; Lee JJ; Ryu MH; Kim SY; Kim DH; Do YR; Lee KH; Oh SJ; Kim YK; Suh CW; Heo DS; Ryoo BY; Kim JK; Song HS; Lee WS; Kim HJ; Bang YJ; Yang SH; Sohn SK; Kang YK;
    Ann Hematol; 2006 Apr; 85(4):257-62. PubMed ID: 16416337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcome of HCV-positive patients with diffuse large B-cell lymphoma treated with rituximab-based chemotherapy.
    Salah-Eldin MA; Ebrahim MA; El-Sadda W
    Ann Hematol; 2014 Nov; 93(11):1903-11. PubMed ID: 24951125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.